aratinga.bio

AT A GLANCE

GENE THERAPY

IMMUNOTHERAPY

ONCOLOGY

CAR T-CELLS

MISSION

aratinga.bio is a preclinical-stage immunotherapy biotech company founded in March 2017 developing novel immunotherapies to treat cancer.

​

We want to harness the immune system to target and kill cancer cells.

To address unmet medical needs, aratinga.bio is developing its proprietary CAR T-cell platform effective against both hematological cancers and solid tumors regardless of the type of previous treatments patients have experienced.

TECHNOLOGY

The lentivector - encoding for the Chimeric Antigen Receptor - is coated with a polymeric envelope. The anti-CD3 targeting moiety grafted at the surface of the polymer directs the synthetic vector towards the T-cells.

aratinga.bio's in vivo technology does not require costly dedicated manufacturing sites to produce modified T-cells in contrast to approved ex vivo CAR T-cell therapies.

The genetic modification to express the CAR is directly generated in the patient.

CAR-T & BEYOND

aratinga.bio's CAR-T platform, represents a welcomed advantage over current recently approved ex vivo CAR-T therapies turning them into more effective, more universal, and safer treatments.

​

The encapsulation technology goes way beyond CAR-T, and includes gene therapy applications.

Thanks to the technology (a synthetic gene delivery platform), one can target any kind of cells as long as you can identify or screen for the corresponding specific receptor.

TEAM

aratinga.bio is led by three founders with complementary experience and skills, with the common ambition of revolutionizing medicine through developing cutting-edge gene therapy-based treatments

JOB

We are constantly seeking exceptional talents to join our team!

No job openings fitting with your profile?

Don't be shy and submit your spontaneous job application

We can’t wait to hear from you!